Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-1 Protein (AA 25-167) (His tag)

PDCD1 Origine: Souris Hôte: HEK-293 Cells Recombinant >95 % as determined by SDS-PAGE.
N° du produit ABIN2181615
  • Antigène Voir toutes PD-1 (PDCD1) Protéines
    PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
    Type de proteíne
    Recombinant
    Attributs du protein
    AA 25-167
    Origine
    • 37
    • 15
    • 6
    • 4
    • 4
    • 3
    • 1
    Souris
    Source
    • 50
    • 5
    • 5
    • 3
    • 3
    • 2
    • 1
    • 1
    HEK-293 Cells
    Purification/Conjugué
    Cette PD-1 protéine est marqué à la His tag.
    Séquence
    AA 25-167
    Attributs du produit
    Mouse PDCD1 /PD1 is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 17.4 kDa. The N-terminus Sequence Analysis is Leu 25. The reducing (R) protein migrates as 25-45 kDa in SDS-PAGE due to different glycosylation.
    Pureté
    >95 % as determined by SDS-PAGE.
    Stérilité
    0.22 μm filtered
    niveau d'endotoxine
    Less than 1.0 EU per μg by the LAL method.
    Top Product
    Discover our top product PDCD1 Protéine
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Buffer
    PBS, pH 7.4
    Conseil sur la manipulation
    Please avoid repeated freeze-thaw cycles.
    Stock
    -20 °C
    Stockage commentaire
    No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
  • Galstyan, Markman, Shatalova, Chiechi, Korman, Patil, Klymyshyn, Tourtellotte, Israel, Braubach, Ljubimov, Mashouf, Ramesh, Grodzinski, Penichet, Black, Holler, Sun, Ding, Ljubimov, Ljubimova: "Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy." dans: Nature communications, Vol. 10, Issue 1, pp. 3850, (2019) (PubMed).

    Ordikhani, Uehara, Kasinath, Dai, Eskandari, Bahmani, Yonar, Azzi, Haik, Sage, Murphy, Annabi, Schatton, Guleria, Abdi: "Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity." dans: JCI insight, Vol. 3, Issue 20, (2018) (PubMed).

    Li, Fang, Zhang, Wang, Song, Shi, Li, Wu, Ren, Wang, Zou, Wang: "Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity." dans: Oncoimmunology, Vol. 5, Issue 2, pp. e1074374, (2016) (PubMed).

  • Antigène
    PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
    Autre désignation
    PD-1 (PDCD1 Produits)
    Synonymes
    CD279 Protein, PD-1 Protein, PD1 Protein, SLEB2 Protein, hPD-1 Protein, hPD-l Protein, Ly101 Protein, Pdc1 Protein, programmed cell death 1 Protein, PDCD1 Protein, Pdcd1 Protein
    Sujet
    Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
    Poids moléculaire
    17.0 kDa
    NCBI Accession
    NP_032824
    Pathways
    Cancer Immune Checkpoints
Vous êtes ici:
Support technique